Department of Pharmacy, Zhongshan Hospital FuDan University, Shanghai, China.
Br J Clin Pharmacol. 2018 Aug;84(8):1706-1718. doi: 10.1111/bcp.13594. Epub 2018 May 24.
The objective of the present study was to investigate the current situation concerning, and risk factors for, vancomycin (VAN)-induced acute kidney injury (VI-AKI) in elderly Chinese patients, to assess outcomes and risk factors in patients who have developed VI-AKI, in order to provide suggestions for improving the prevention and treatment of this condition in these patients.
We retrospectively identified elderly older inpatients who had received four or more doses of VAN treatment. We compared patients with VI-AKI with those who received VAN treatment and had not developed AKI (NO-AKI). We defined VI-AKI as developing AKI during VAN therapy or within 3 days after withdrawal of VAN.
A total of 647 out of 862 elderly inpatients were included in the study. Among those excluded, in 89.3% of cases (192/215) this was because of lack of data on serum creatinine (SCr). Among included patients, 32.5% (210/647) of patients received therapeutic drug monitoring (TDM) during VAN therapy. In 66.9% of cases (424/634), there was insufficient TDM, and in 3.9% (25/634) this was appropriate. A total of 102 patients had confirmed VI-AKI, with an incidence of 15.8% (102/647). Multiple logistic regression analysis revealed that hyperuricaemia [odds ratio (OR) = 3.045; P = 0.000)], mechanical ventilation (OR = 1.906; P = 0.022) and concomitant vasopressor therapy (OR = 1.919; P = 0.027) were independent risk factors for VI-AKI; higher serum albumin (OR = 0.885; P = 0.000) was determined to be an independent protective factor for VI-AKI.
For the elderly Chinese patients treated with VAN, there was insufficient monitoring of SCr, too little use of VAN TDM, and lower rate of patients whose VAN though serum concentrations were not obtained at the correct time. We recommend that hospital managers increase investment in clinical pharmacists, to strengthen professional management. Patients with concomitant hyperuricaemia and on mechanical ventilation and vasopressor therapy should be paid more attention, and a higher serum albumin was determined to be an independent protective factor for VI-AKI.
本研究旨在探讨中国老年患者万古霉素(VAN)诱导的急性肾损伤(VI-AKI)的现状和危险因素,评估发生 VI-AKI 患者的结局和危险因素,为改善此类患者的预防和治疗提供建议。
我们回顾性纳入接受 4 剂或以上 VAN 治疗的老年住院患者。我们将 VI-AKI 患者与接受 VAN 治疗且未发生 AKI(NO-AKI)的患者进行比较。我们将 VI-AKI 定义为在 VAN 治疗期间或 VAN 停药后 3 天内发生 AKI。
共纳入 862 例老年住院患者中的 647 例,其中 89.3%(192/215)因缺乏血清肌酐(SCr)数据而被排除。在纳入的患者中,32.5%(210/647)在 VAN 治疗期间接受了治疗药物监测(TDM)。在 66.9%(424/634)的病例中,TDM 不足,3.9%(25/634)的 TDM 是合适的。共有 102 例患者确诊为 VI-AKI,发生率为 15.8%(102/647)。多因素 logistic 回归分析显示,高尿酸血症(OR=3.045;P=0.000)、机械通气(OR=1.906;P=0.022)和同时使用血管加压药(OR=1.919;P=0.027)是 VI-AKI 的独立危险因素;血清白蛋白较高(OR=0.885;P=0.000)是 VI-AKI 的独立保护因素。
对于接受 VAN 治疗的中国老年患者,SCr 监测不足,VAN TDM 应用较少,未能在正确时间获得 VAN 血药浓度的患者比例较低。我们建议医院管理者增加对临床药师的投入,加强专业管理。对于同时伴有高尿酸血症、机械通气和血管加压药治疗的患者应给予更多关注,较高的血清白蛋白是 VI-AKI 的独立保护因素。